Diagnostic radiopharmaceuticals

Diagnostic radiopharmaceuticals are a specialized class of agents used in nuclear medicine for non-invasive imaging of organs, tissues, and biological functions. These compounds consist of a radionuclide (radioisotope) attached to a pharmaceutical carrier that determines its biodistribution. Unlike therapeutic radiopharmaceuticals, which deliver cytotoxic radiation to treat disease (e.g., in oncology), diagnostic radiopharmaceuticals emit gamma rays or positrons detectable by external imaging equipment such as SPECT or PET scanners.

Their use is essential in oncology, cardiology, neurology, nephrology, and endocrine studies for diagnosis, staging, monitoring of disease progression, and treatment efficacy evaluation.

---

1. Composition and Functionality

A diagnostic radiopharmaceutical is composed of:

• Radionuclide: Emits detectable radiation (gamma rays or positrons)

• Pharmaceutical moiety: Directs the compound to specific organs or biological targets

Key features:

• Administered in trace (non-pharmacological) amounts

• Designed to mimic physiological substrates (e.g., glucose, iodine)

• Short half-lives to limit patient radiation exposure

• Radiotracers are not intended to exert therapeutic effects

---

2. Classification by Imaging Modality

Imaging Modality	Radiation Type	Radionuclides Used	Detection System
SPECT (Single Photon Emission Computed Tomography)	Gamma rays (γ)	99mTc, 123I, 111In, 67Ga	Gamma camera
PET (Positron Emission Tomography)	Positrons (β⁺)	18F, 11C, 13N, 15O, 68Ga	PET scanner

3. Commonly Used Diagnostic Radiopharmaceuticals

Radiopharmaceutical	Radionuclide	Indication	Imaging Type
Fludeoxyglucose (18F-FDG)	18F	Cancer, brain metabolism, cardiac viability	PET
Technetium-99m sestamibi	99mTc	Myocardial perfusion, parathyroid adenomas	SPECT
Technetium-99m MDP	99mTc	Bone scans for metastases/fractures	SPECT
Technetium-99m HIDA (DISIDA, Mebrofenin)	99mTc	Hepatobiliary imaging (cholecystitis, bile leaks)	SPECT
Iodine-123 or Iodine-131 (low dose)	123I/131I	Thyroid imaging	SPECT
Gallium-68 DOTATATE	68Ga	Neuroendocrine tumors (NETs)	PET
Gallium-67 citrate	67Ga	Infections, inflammation, lymphoma	SPECT
Indium-111 WBC	111In	Infection, abscess localization	SPECT
Rubidium-82 chloride	82Rb	Myocardial perfusion PET	PET

4. Organ-Targeted Diagnostic Radiopharmaceuticals

• Brain:

  • 18F-FDG: for metabolism (epilepsy, dementia)

  • 123I ioflupane (DaTscan): for Parkinsonian syndromes

• Cardiac:

  • 99mTc-sestamibi: myocardial perfusion

  • 82Rb: PET perfusion imaging

• Lung:

  • 99mTc-MAA: perfusion scan (PE evaluation)

  • 99mTc-DTPA: ventilation scan

• Bone:

  • 99mTc-MDP/HDP: detection of skeletal metastases

• Thyroid:

  • 123I or low-dose 131I: functional thyroid imaging

• Liver and Biliary Tract:

  • 99mTc-HIDA: bile duct patency and gallbladder ejection fraction

• Infection/Inflammation:

  • 111In-WBC, 67Ga-citrate: abscess, osteomyelitis

---

5. Mechanism of Localization

Mechanisms that dictate radiopharmaceutical uptake include:

• Physiologic trapping (e.g., FDG in metabolically active cells)

• Phagocytosis (e.g., sulfur colloid in Kupffer cells)

• Compartmental localization (e.g., MAA in capillary bed)

• Ion exchange (e.g., bone agents binding to hydroxyapatite)

• Receptor binding (e.g., DOTATATE to somatostatin receptors)

---

6. Administration and Dosage

• Most are administered intravenously in microdoses

• Administered doses vary by radiopharmaceutical and body weight

• Often used with CT fusion (SPECT/CT or PET/CT) for anatomical correlation

Example:

• 18F-FDG: 5–10 mCi IV; imaging 60 min post-injection

• 99mTc-MDP: 20–30 mCi IV; imaging 2–4 hours later

---

7. Pharmacokinetics

• Rapid distribution in vascular and interstitial compartments

• Short physical half-lives for safety

  • 99mTc: ~6 hours

  • 18F: ~110 minutes

• Cleared through renal or hepatobiliary pathways

• Minimal pharmacodynamic action due to trace doses

---

8. Radiation Safety Considerations

• Patient exposure typically ranges from 2–15 mSv per scan

• ALARA (As Low As Reasonably Achievable) principle is enforced

• Radiation exposure is justified only when:

  • Diagnostic value outweighs risk

  • No alternative non-radiating test is available

---

9. Contraindications and Precautions

Situation	Risk or Concern	Action
Pregnancy	Fetal radiation exposure	Use only if benefit outweighs risk; consider ultrasound/MRI alternatives
Lactation	Potential radioactivity in breast milk	Temporary interruption recommended for specific agents
Renal impairment	Delayed clearance → higher radiation dose	Dose adjustment or use of hepatobiliary agents
Allergy	Rare; hypersensitivity to carrier	Pre-assess history; substitute if possible

10. Drug Interactions

Diagnostic radiopharmaceuticals may be affected by:

• Medications:

  • Steroids: Can alter FDG uptake in PET scans

  • Amiodarone: Can affect thyroid uptake of iodine

  • Antipsychotics or SSRIs: May interfere with DaTscan binding

• Dietary Restrictions:

  • High glucose affects FDG uptake

  • Iodine-rich food or supplements interfere with 123I scans

Proper patient preparation is essential for accurate imaging.

---

11. Clinical Utility in Disease Detection

Condition	Preferred Radiopharmaceutical	Diagnostic Value
Alzheimer’s Disease	18F-FDG PET, Amyloid PET	Hypometabolism, amyloid deposition
Cancer Staging	18F-FDG, 68Ga-DOTATATE	High sensitivity for metastases
Pulmonary Embolism	99mTc-MAA (V/Q scan)	Perfusion defect
Cardiac Ischemia	99mTc-sestamibi, 82Rb	Perfusion mismatch
Infection/Sepsis	111In-WBC, 67Ga	Site localization of infection

12. Regulatory and Quality Control

• Radiopharmaceuticals are regulated by national nuclear authorities (e.g., US FDA, EMA, IAEA)

• Production follows Good Manufacturing Practices (GMP)

• Radiochemical purity, sterility, pyrogenicity must be tested

• Labeled with short-lived isotopes; on-site cyclotrons or generator systems may be required

---

13. Trends and Innovations

• Hybrid imaging: PET/CT, SPECT/CT, and PET/MRI integration

• Targeted molecular imaging: Using receptor-specific tracers (e.g., PSMA-PET for prostate cancer)

• Theranostics: Combining diagnostics with therapeutics (e.g., 68Ga-DOTATATE for imaging + 177Lu-DOTATATE for therapy)

• Artificial Intelligence (AI): Enhancing image interpretation and quantification

• Total-body PET: Offers higher resolution, lower dose, and whole-body dynamic studies

---

14. Limitations

• Availability: PET tracers like 18F-FDG require cyclotron and radiopharmacy

• Radiation exposure: Though minimal, remains a limiting factor in pediatric and repeat imaging

• False positives/negatives: FDG uptake in inflammation/infection; low uptake in indolent tumors

• Cost: PET and SPECT scans are expensive and not always reimbursed